Syndax Pharmaceuticals, Inc.
SNDX
$24.10
$0.602.55%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -12.02% | 15.49% | 15.32% | 9.90% | -11.94% |
| Total Depreciation and Amortization | 0.00% | -- | -- | -- | -100.00% |
| Total Amortization of Deferred Charges | -101.61% | 12.73% | -50.89% | 273.33% | -- |
| Total Other Non-Cash Items | -23.80% | 25.55% | 53.50% | -26.80% | 4.30% |
| Change in Net Operating Assets | 49.71% | 12.61% | -53.48% | -164.11% | 115.23% |
| Cash from Operations | 1.48% | 19.66% | 7.74% | -65.82% | 7.92% |
| Capital Expenditure | 57.25% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 12.51% | 73.23% | -55.51% | 135.00% | -409.71% |
| Cash from Investing | 12.63% | 72.92% | -55.51% | 135.00% | -409.71% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -5.75% | 1,039.38% | -40.75% | -75.35% | 21.79% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -5.75% | 1,039.38% | -40.75% | -99.73% | 11,114.49% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 120.35% | 118.02% | -50,296.67% | -100.43% | -23.74% |